Pharmacology, Toxicology and Pharmaceutical Science
Melanoma
100%
Neoplasm
65%
Malignant Neoplasm
42%
Placebo
40%
Metastatic Melanoma
36%
Pembrolizumab
35%
Dendritic Cell Vaccine
30%
Recurrent Disease
29%
Nivolumab
25%
Ipilimumab
25%
Adverse Event
24%
Phase II Trials
23%
Disease
22%
Ovary Cancer
22%
Angiopeptin
21%
Monotherapy
21%
Diarrhea
20%
Disease Exacerbation
19%
Symptom
18%
Solid Malignant Neoplasm
17%
Granulocyte Colony Stimulating Factor
17%
Carcinoid Syndrome
15%
Chemotherapy
13%
Neuroendocrine Tumor
13%
Immunotherapy
12%
Octreotide
12%
Maximum Tolerated Dose
12%
Human Study
11%
Stromal Cell Derived Factor 1
11%
Immune Checkpoint Inhibitor
11%
Everolimus
11%
Temsirolimus
11%
Irinotecan
11%
Tumor Microenvironment
11%
Ifosfamide
11%
Aurora Kinase Inhibitor
11%
Hydralazine
11%
Inhibitory Guanine Nucleotide Binding Protein
11%
Tilsotolimod
11%
Vaccination Policy
11%
Randomized Clinical Trial
11%
Indoximod
11%
Litronesib
11%
Cytotoxicity
11%
Etoposide
11%
Lethality
11%
Indoleamine 2,3 Dioxygenase
11%
Renal Cell Carcinoma
11%
Sarcoma
11%
Sodium Valproate
11%
Keyphrases
Melanoma
53%
Ipilimumab
36%
Advanced Melanoma
35%
Pembrolizumab
35%
Double-strand Breaks
27%
Histone H3
23%
Randomized Double-blind
23%
DNA Repair
23%
Methylation
23%
Prospective Randomized Trial
23%
Lysine
23%
Dendritic Cell Vaccine
23%
Prevent Recurrence
23%
Tumor Lysate
23%
Non-homologous End Joining
23%
Monotherapy
21%
H3K36me3
19%
Checkpoint Inhibitors
17%
Phase II Trial
17%
Metnase
15%
Histone Methylation
15%
Stage III-IV
15%
Phase II Study
13%
High-risk Melanoma
13%
Metastatic Melanoma
13%
Nivolumab
13%
Placebo
12%
Placebo-controlled
12%
Melanoma Recurrence
12%
Neoadjuvant
11%
Phase I Study
11%
CXCR4 Protein
11%
Homologous Recombination
11%
Replication Stress
11%
Irinotecan
11%
AMG 900
11%
Neoantigen
11%
Stage IV Non-small Cell Lung Cancer
11%
Temsirolimus
11%
Expert Insights
11%
Tumor Response
11%
Previously Untreated
11%
Phase Ib Study
11%
Telaglenastat
11%
Melanoma Patients
11%
Checkpoint Inhibitor Therapy
11%
Indoximod
11%
Eg5 Inhibitor
11%
Litronesib
11%
Vemurafenib
11%
Medicine and Dentistry
Nodular Melanoma
66%
Neoplasm
57%
Dendritic Cell Vaccine
42%
Recurrent Disease
40%
Metastatic Melanoma
35%
Dendritic Cell
34%
Placebo
31%
Immune Checkpoint Inhibitor
23%
Pembrolizumab
23%
Adverse Event
20%
Immunotherapy
15%
Disease Free Survival
13%
Clinical Trial
12%
Monotherapy
11%
Systemic Therapy
11%
Everolimus
11%
Colony Forming Cell
11%
Cytotoxicity
11%
Lymphatic Malformation
11%
Stromal Cell Derived Factor 1
11%
Etoposide
11%
Inhibitory Guanine Nucleotide Binding Protein
11%
Tilsotolimod
11%
Ifosfamide
11%
Malignant Neoplasm
11%
Myeloid Progenitor Cell
11%
Immune Checkpoint Blockade
11%
Engraftment
11%
Stem Cell
11%
Clear Cell Renal Cell Carcinoma
11%
Vemurafenib
11%
Seviprotimut L
11%
Melanoma Vaccine
11%
Ipilimumab
11%
Subgroup Analysis
11%
Tumor Microenvironment
11%
Randomized Clinical Trial
11%
Alpelisib
11%
Oncology
11%
Mammary Analog Secretory Carcinoma
11%
Ovarian Cancer
11%
Disease
9%
MEK Inhibitor
8%
Overall Survival
8%
Symptom
7%
Pancreatic Cancer Cell Line
7%
Targeted Therapy
7%
Colon Cancer Cell Line
7%
Target Organ
7%
CTLA-4
7%
